(Q36368045)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Ronald J Mandel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Fredric P Manfredsson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Kevin D Foust

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Aaron Rising

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sharon Reimsnider

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Kevin Nash

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

18 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

463-483

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16412695%20AND%20SRC:MED&resulttype=core&format=json

Clinical gene transfer studies for hemophilia B.

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Gene therapy of severe combined immunodeficiencies

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Adeno-associated virus vectors in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated virus (AAV) vectors in the CNS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Recombinant adeno-associated viral vectors in the nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Gene transfer for neurologic disease: agencies, policies, and process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

AAV serotype 2 vectors preferentially integrate into active genes in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated virus vectors: activity and applications in the CNS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Genetics of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Mitochondrial dysfunction in Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Long-duration response to levodopa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Genetics of parkin-linked disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Localized striatal delivery of GDNF as a treatment for Parkinson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Viral restoration of dopamine to the nucleus accumbens is sufficient to induce a locomotor response to amphetamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

A Clinically Relevant Unilateral Rat Model of Parkinsonian Akinesia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Continuous and intermittent levodopa differentially affect basal ganglia function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Animal models of neurological deficits: how relevant is the rat?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Regulation of dopamine production by genetically modified primary fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Subthalamic GAD gene therapy in a Parkinson's disease rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Pathogenesis of nigral cell death in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated virus-mediated antiapoptotic gene delivery: in vivo gene therapy for neurological disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Translating cell biology into therapeutic advances in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Amyloid beta-peptide: the inside story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

The cholinergic hypothesis of geriatric memory dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Cholinergic strategies for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

The role of cortical cholinergic afferent projections in cognition: impact of new selective immunotoxins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Hopes remain for an Alzheimer's vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Defining molecular targets to prevent Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Huntington's disease: CAG genetics expands neurobiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Trinucleotide repeat length and clinical progression in Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Clinical markers of early disease in persons near onset of Huntington's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Recent advances on the pathogenesis of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Brain-derived neurotrophic factor in Huntington disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Molecular medicine for the brain: silencing of disease genes with RNA interference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Allele-specific silencing of dominant disease genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Glutamine repeats and neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

The frequency of lysosomal storage diseases in The Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Gene therapy for lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

The molecular basis of lysosomal storage diseases and their treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Globoid Cell Leukodystrophy (Krabbe's Disease): Update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Effective gene therapy for an inherited CNS disease in a large animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Combined injection of rAAV with mannitol enhances gene expression in the rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Gene therapy for malignant glioma: current clinical status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Thymidine kinase-mediated killing of rat brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Gene therapy for human malignant brain tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Antitumor effect of an adeno-associated virus vector containing the human interferon-beta gene on experimental intracranial human glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

An in vitro study on the suppressive effect of glioma cell growth induced by plasmid-based small interference RNA (siRNA) targeting human epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

RNA interference against a glioma-derived allele of EGFR induces blockade at G2M.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Complex genetics of amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Gene therapy for ALS delivers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Transgenic-mouse model of amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Immunohistochemical study on superoxide dismutases in spinal cords from autopsied patients with amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neuroprotective adeno-associated virus Bcl-xL gene transfer in models of motor neuron disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated viral vector-mediated neurotrophin gene transfer in the injured adult rat spinal cord improves hind-limb function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Rescue and sprouting of motoneurons following ventral root avulsion and reimplantation combined with intraspinal adeno-associated viral vector-mediated expression of glial cell line-derived neurotrophic factor or brain-derived neurotrophic factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Gene therapy of chronic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated viral transfer of opioid receptor gene to primary sensory neurons: a strategy to increase opioid antinociception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

The changing landscape of ischaemic brain injury mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

The problem of assessing effective neuroprotection in experimental cerebral ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated virus vector-mediated bcl-2 gene transfer into post-ischemic gerbil brain in vivo: prospects for gene therapy of ischemia-induced neuronal death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neuropathological and behavioral consequences of adeno-associated viral vector-mediated continuous intrastriatal neurotrophin delivery in a focal ischemia model in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Amelioration of ischaemia-induced neuronal death in the rat striatum by NGF-secreting neural stem cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Anterograde delivery of brain-derived neurotrophic factor to striatum via nigral transduction of recombinant adeno-associated virus increases neuronal death but promotes neurogenic response following stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Suppression of insult-induced neurogenesis in adult rat brain by brain-derived neurotrophic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Recombinant adeno-associated virus vector expressing glial cell line-derived neurotrophic factor reduces ischemia-induced damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Monogenic idiopathic epilepsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Channelopathies as a genetic cause of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

The clinical potential of antiepileptic gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Therapeutic liabilities of in vivo viral vector tropism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Galanin and galanin receptors in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Galanin--10 years with a neuroendocrine peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Galanin plasticity in the cholinergic basal forebrain in Alzheimer's disease and transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neuropeptide Y: the universal soldier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neuropeptide Y and epilepsy: recent progress, prospects and controversies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Preferential expression of an AAV-2 construct in NOS-positive interneurons following intrastriatal injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Remote control of gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Hypoxia-regulated transgene expression in experimental retinal and choroidal neovascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Ecdysone-inducible gene expression in mammalian cells and transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

A regulatory system for use in gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

A humanized system for pharmacologic control of gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Regulation of gene expression in adeno-associated virus vectors in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Long-term regulated expression of growth hormone in mice after intramuscular gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Exogenous control of mammalian gene expression through modulation of RNA self-cleavage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Regulatable gene expression systems for gene therapy applications: progress and future challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Immune responses to adenovirus and adeno-associated virus in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Gene therapy death prompts review of adenovirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

Neuropathological classification of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Thrombolytic treatment of acute cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.11.009